Drug Trial Radar · NCT07924059
Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
144
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Sep 2028
Study completion Sep 2029
Sponsor
- Lead sponsor
- Ascendis Pharma A/SIndustry
- Sponsor type
- Industry
- First posted
- Nov 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pivotal trial is being conducted to evaluate the efficacy, safety and tolerability of dual therapy with navepegritide and lonapegsomatropin administered as separate subcutaneous (SC) injections once weekly in children with achondroplasia (ACH) aged 2 to 17 years.
Conditions
- Achondroplasia
Interventions
Dual therapy with navepegritide and lonapegsomatropinDrug
Administered weekly as two separate SC injections. Treatment duration of up to 104 weeks
Dual therapy with navepegritide and placebo for lonapegsomatropinDrug
Administered as two separate SC injections. Treatment duration of up to 52 weeks of navepegritide and placebo for lonapegsomatropin followed by 52 weeks of navepegritide and lonapegsomatropin.
Dual therapy with lonapegsomatropin and placebo for navepegritideDrug
Administered as two separate SC injections. Treatment duration of up to 52 weeks of lonapegsomatropin and placebo for navepegritide followed by 52 weeks of navepegritide and lonapegsomatropin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Growth Velocity (AGV)Time frame: 52 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.